Forbes

Psychology Aims For A Unified Theory Of Cognition And AI Will Be A Big Help To Get There

Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. In today’s column, I examine the ongoing pursuit by psychology ...
Seeking Alpha

Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia

– ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally – – Novel transdermal formulation of ALTO-101 exhibited favorable ...
Pharmabiz

Alto Neuroscience completes enrollment in phase 2 proof-of-concept study of ALTO-101 in cognitive impairment associated with schizophrenia

Mountain View, California Monday, February 16, 2026, 18:00 Hrs [IST] ...
KTLA

Damona Announces Publication of Preclinical Proof-of-Concept Data for DPX-101 (GL-II-73) Demonstrating Symptomatic and Disease-Modifying Potential for the Treatment of ...

TORONTO, Feb. 4, 2025 /PRNewswire/ -- Damona Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing small molecules for the treatment and prevention of ...
Morningstar

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), ...
Business Wire

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for ...